To read the full story, subscribe or sign in.

Neophore adds $21M for MMR-targeting small-molecule approach

March 9, 2021

LONDON – Neophore Ltd. announced the close of a $21 million series B that will enable it to further advance a portfolio of small-molecule DNA mismatch repair (MMR) inhibitors over the next 2.5 years.

BioWorld Financings Cancer Series B

Today's news in brief

BioWorld

BioWorld briefs for April 17, 2026.

Man holding raised arm with illustrated overlay of nerves

Biohaven reports details on discovery of BHV-2100

BioWorld Science

Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...

New GABA(B) receptor PAMs revealed in Addex Pharma patents

BioWorld Science

Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...

Elderly woman holding illustration of brain with missing puzzle piece

Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’

BioWorld

The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...

Novel caspase-2 inhibitor shows in vivo neuroprotective effects

BioWorld Science

Caspase-2-mediated cleavage of tau at Asp314 generates a neurotoxic fragment, Δtau314, that drives early synaptic dysfunction in Alzheimer’s disease (AD) and...